Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.255 USD | -0.82% | -5.86% | -0.35% |
04-19 | US FDA mandates label updates on CAR-T cancer therapies | RE |
04-05 | Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication | MT |
Sales 2024 * | 88.57M 7.09B | Sales 2025 * | 115M 9.21B | Capitalization | 219M 17.51B |
---|---|---|---|---|---|
Net income 2024 * | -96M -7.69B | Net income 2025 * | -31M -2.48B | EV / Sales 2024 * | 2.47 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.9 x |
P/E ratio 2024 * |
-2.09
x | P/E ratio 2025 * |
-6.1
x | Employees | 274 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.68% |
Latest transcript on 2seventy bio, Inc.
1 day | -0.82% | ||
1 week | -5.86% | ||
Current month | -20.47% | ||
1 month | -14.21% | ||
3 months | +32.14% | ||
6 months | +66.86% | ||
Current year | -0.35% |
Managers | Title | Age | Since |
---|---|---|---|
Chip Baird
CEO | Chief Executive Officer | 52 | - |
Nick Leschly
CHM | Chairman | 51 | 03/05/21 |
Susan Abu-Absi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Lynch
BRD | Director/Board Member | 65 | 14/10/21 |
Nick Leschly
CHM | Chairman | 51 | 03/05/21 |
Chip Baird
CEO | Chief Executive Officer | 52 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.23% | 2 M€ | -25.75% | ||
0.03% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 4.255 | -0.82% | 311,544 |
25/04/24 | 4.29 | +0.47% | 3,725,775 |
24/04/24 | 4.27 | -7.78% | 470,298 |
23/04/24 | 4.63 | -0.43% | 292,143 |
22/04/24 | 4.65 | +2.88% | 406,373 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.35% | 219M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- TSVT Stock